Asset Management One
CRSP icon

Asset Management One’s CRISPR Therapeutics CRSP Stock Holding History

Asset Management One’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,132
Closed -$1.19M – 924
2025
Q4 		$1.19M Hold
22,132
– – ﹤0.01% 750
2025
Q3 		$1.43M Sell
22,132
-13,854
-38% -$795K ﹤0.01% 739
2025
Q2 		$1.75M Hold
35,986
– – 0.01% 710
2025
Q1 		$1.22M Hold
35,986
– – ﹤0.01% 766
2024
Q4 		$1.44M Hold
35,986
– – ﹤0.01% 767
2024
Q3 		$1.69M Hold
35,986
– – 0.01% 762
2024
Q2 		$1.94M Buy
35,986
+8,886
+33% +$514K 0.01% 734
2024
Q1 		$1.85M Hold
27,100
– – 0.01% 757
2023
Q4 		$1.74M Buy
+27,100
New +$1.5M 0.01% 770
2022
Q2 		– Sell
-100
Closed -$6K – 1043
2022
Q1 		$6K Hold
100
– – ﹤0.01% 1035
2021
Q4 		$7K Hold
100
– – ﹤0.01% 1044
2021
Q3 		$11K Sell
100
-200
-67% -$25.1K ﹤0.01% 1037
2021
Q2 		$48K Sell
300
-3,910
-93% -$476K ﹤0.01% 1028
2021
Q1 		$512K Sell
4,210
-6,922
-62% -$1.05M ﹤0.01% 916
2020
Q4 		$1.76M Hold
11,132
– – 0.01% 800
2020
Q3 		$931K Buy
+11,132
New +$987K ﹤0.01% 841

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Asset Management One's CRSP Position: Q1 2026 in Review

Asset Management One sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 22,132 shares — an estimated $1.19M sold.

Asset Management One first reported a position in CRSP in Q3 2020 and held it in 16 quarters. The position peaked at $1.94M in Q2 2024. 491 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Asset Management One reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Asset Management One sold 22,132 CRISPR Therapeutics shares in Q1 2026, an estimated $1.19M.
  • Asset Management One first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 16 quarters.
  • Asset Management One's CRISPR Therapeutics position peaked at $1.94M in Q2 2024.
  • 491 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Asset Management One's 13F filing for Q1 2026, filed 8 May 2026.